1. Home
  2. APLM vs GDHG Comparison

APLM vs GDHG Comparison

Compare APLM & GDHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • GDHG
  • Stock Information
  • Founded
  • APLM 2016
  • GDHG 2008
  • Country
  • APLM United States
  • GDHG China
  • Employees
  • APLM N/A
  • GDHG N/A
  • Industry
  • APLM Blank Checks
  • GDHG Services-Misc. Amusement & Recreation
  • Sector
  • APLM Finance
  • GDHG Consumer Discretionary
  • Exchange
  • APLM Nasdaq
  • GDHG Nasdaq
  • Market Cap
  • APLM 7.7M
  • GDHG 9.0M
  • IPO Year
  • APLM N/A
  • GDHG 2023
  • Fundamental
  • Price
  • APLM $6.71
  • GDHG $0.51
  • Analyst Decision
  • APLM Strong Buy
  • GDHG
  • Analyst Count
  • APLM 2
  • GDHG 0
  • Target Price
  • APLM $425.00
  • GDHG N/A
  • AVG Volume (30 Days)
  • APLM 42.6K
  • GDHG 4.8M
  • Earning Date
  • APLM 04-15-2025
  • GDHG 04-08-2025
  • Dividend Yield
  • APLM N/A
  • GDHG N/A
  • EPS Growth
  • APLM N/A
  • GDHG N/A
  • EPS
  • APLM N/A
  • GDHG N/A
  • Revenue
  • APLM $2,101,000.00
  • GDHG $22,333,251.00
  • Revenue This Year
  • APLM N/A
  • GDHG N/A
  • Revenue Next Year
  • APLM N/A
  • GDHG N/A
  • P/E Ratio
  • APLM N/A
  • GDHG N/A
  • Revenue Growth
  • APLM 70.54
  • GDHG N/A
  • 52 Week Low
  • APLM $6.20
  • GDHG $0.39
  • 52 Week High
  • APLM $63.00
  • GDHG $21.65
  • Technical
  • Relative Strength Index (RSI)
  • APLM 43.33
  • GDHG 38.04
  • Support Level
  • APLM $6.20
  • GDHG $0.39
  • Resistance Level
  • APLM $8.00
  • GDHG $5.25
  • Average True Range (ATR)
  • APLM 1.37
  • GDHG 0.92
  • MACD
  • APLM -0.18
  • GDHG -0.19
  • Stochastic Oscillator
  • APLM 9.44
  • GDHG 2.47

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About GDHG Golden Heaven Group Holdings Ltd.

Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.

Share on Social Networks: